PLYMOUTH MEETING, Pa., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that PharmaVoice, one of the leading industry publications in the life sciences industry, has selected Dr. Niranjan Sardesai as one of its 100 most inspiring leaders of 2015. Dr. Sardesai is the Chief Operating Officer of Inovio, a leading developer of innovative cancer and infectious disease treatment and preventive therapies. Those chosen for this elite group are selected for their positive contributions as leaders who think differently, address the big challenges facing the industry, and lead teams through inspiration. These leaders will gather in New York City on September 17, 2015 for a celebration of their selection.
Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He is responsible for leading the company's product development programs in infectious disease and cancer immunotherapies and delivery systems. He has secured over $130 million in non-dilutive funding through government and NGO grants and contracts and was Inovio's lead executive in completing Inovio's two big pharma licensing deals with Roche and MedImmune in the last two years.
Under his leadership the company has advanced immunotherapy programs for cervical dysplasia, HIV, and cancers that are now in clinical studies. He currently serves as the principal investigator on an NIAID-funded HVDDT contract for the development of HIV vaccines and DARPA-funded Ebola vaccine and therapeutics programs.
Prior to Inovio, Dr. Sardesai oversaw R&D and expansion of the oncology portfolio at Fujirebio Diagnostics, Inc. Products developed under his leadership include new-to-the-world tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.
Dr. Sardesai said, "I am honored to be named as one of the 100 most inspiring people in the life science industry. This prestigious recognition by PharmaVoice has been possible because of the dedication of the Inovio people in our R&D, business development and commercial functions."
Dr. J. Joseph Kim, President and CEO, said, "According to PharmaVoice, their 100 Award is a means to celebrate the men and women who provide inspiration to their peers, colleagues, and companies through their innovative and motivation approaches to addressing the industry's myriad challenges. We knew that about Niranjan already, and all of us at Inovio are proud that he has been counted among these honored few."
Established more than 10 years ago by PharmaVoice magazine, the PharmaVoice 100 is an annual list of individuals recognized for their positive contributions to the life science industry. Selected from thousands of nominations, the distinguished honorees are selected based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and even competitors, have affected positive changes in their own organizations, as well as give back to their communities and other philanthropic causes.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended June 30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.